Literature DB >> 2845849

Cyclic AMP-dependent protein kinase as a part of the possible down-regulating pathway in the antigen receptor-regulated cytotoxic T lymphocyte conjugate formation and granule exocytosis.

M V Sitkovsky1, G Trenn, H Takayama.   

Abstract

Screening activities of cytotoxic T lymphocytes (CTL) are viewed as a cycle of engagements and disengagements with target cells. One of the unexplained features of CTL activation is a biochemical mechanism of an "off" signal, which would result in disengagement of CTL from the target cell and termination of exocytosis of granules. Data are presented that suggest that cAMP dependent-protein kinase (PK-A) inhibits both early and late stages of antigen receptor-regulated CTL activation and may be a part of such an off signaling pathway.

Mesh:

Substances:

Year:  1988        PMID: 2845849     DOI: 10.1111/j.1749-6632.1988.tb36352.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

Review 1.  Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

Authors:  Michail V Sitkovsky; Stephen Hatfield; Robert Abbott; Bryan Belikoff; Dmitriy Lukashev; Akio Ohta
Journal:  Cancer Immunol Res       Date:  2014-07       Impact factor: 11.151

Review 2.  A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.

Authors:  Stephen M Hatfield; Michail Sitkovsky
Journal:  Curr Opin Pharmacol       Date:  2016-07-17       Impact factor: 5.547

Review 3.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.

Authors:  Bruce N Cronstein; Michail Sitkovsky
Journal:  Nat Rev Rheumatol       Date:  2016-11-10       Impact factor: 20.543

4.  Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes.

Authors:  B Hofmann; P Nishanian; T Nguyen; P Insixiengmay; J L Fahey
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

Review 5.  The adenosinergic immunomodulatory drugs.

Authors:  Akio Ohta; Michail Sitkovsky
Journal:  Curr Opin Pharmacol       Date:  2009-06-17       Impact factor: 5.547

Review 6.  Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy.

Authors:  Stephen M Hatfield; Michail V Sitkovsky
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 7.  Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells.

Authors:  M Sitkovsky; D Lukashev; S Deaglio; K Dwyer; S C Robson; A Ohta
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

8.  From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy.

Authors:  Dmitriy Lukashev; Michail Sitkovsky; Akio Ohta
Journal:  Purinergic Signal       Date:  2007-01-24       Impact factor: 3.765

Review 9.  Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.

Authors:  Joseph M Steingold; Stephen M Hatfield
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.